Early results of Preserflo MicroShunt implantation in primary open-angle glaucoma
A. N. Zhuravleva,
S. Yu. Petrov,
A. V. Starostina,
O. M. Kalinina,
O. M. Filippova,
S. M. Kosakyan,
O. I. Markelova https://doi.org/10.21516/2072-0076-2025-18-4-34-38
Abstract
Purpose: to evaluate the efficacy and safety of Preserflo MicroShunt implantation in patients with primary open-angle glaucoma (POAG) as the first and second glaucoma surgery in the early postoperative period.
Material and methods. Single-center prospective non-randomized study of Preserflo MicroShunt implantation in 12 patients (12 eyes) aged 60,4 ± 17,8 with moderate and advanced POAG with an average IOP of 30.3 ± 9.1 mm Hg. IOP was determined at 1, 3, 7 days, 2 weeks, 1 and 3 months after surgery.
Results. The IOP level was 10.2 ± 5.0, 9.4 ± 4.4, 11.3 ± 4.5, 10.8 ± 4.2, 12.7 ± 5.6 and 13.0 ± 6.1 mm Hg, respectively. Baseline average visual acuity was 0.5 ± 0.3, unchanged either on day 7 or by 3 month. Hypotony £ 6 mmHg was in 4 cases, with a flat anterior chamber and choroidal effusion without Seidel positive leakage in 2 cases, without anterior chamber reformation. In 5 cases, IOP increase required bleb needling filtration, and in 2 cases — the medication therapy restart.
Conclusion. Preserflo MicroShunt implantation in patients with POAG is an effective and safe procedure for up to 3 months after surgery.
About the Authors
A. N. Zhuravleva
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Anastasia N. Zhuravleva — Cand. of Med. Sci., senior researcher, glaucoma department
14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062
S. Yu. Petrov
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Sergey Yu. Petrov — Dr. of Med. Sci., head of the glaucoma department
14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062
A. V. Starostina
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Anna V. Starostina — Cand. of Med. Sci., researcher, glaucoma department
14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062
O. M. Kalinina
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Olga M. Kalinina — Cand. of Med. Sci., head of glaucoma unit
14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062
O. M. Filippova
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Olga M. Filippova — Cand. of Med. Sci., researcher, glaucoma department
14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062
S. M. Kosakyan
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Srbui M. Kosakyan — Cand. of Med. Sci., ophthalmologist, glaucoma department
14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062
O. I. Markelova
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Oksana I. Markelova — junior researcher
14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062
References
1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90 (3): 262–7. doi: 10.1136/bjo.2005.081224
2. Tielsch JM, Katz J, Singh K, et al. A population-based evaluation of glaucoma screening: the Baltimore Eye Survey. Am J Epidemiol. 1991; 134 (10): 1102–10. doi: 10.1093/oxfordjournals.aje.a116013
3. Sotimehin AE, Ramulu P.Y. Measuring disability in glaucoma. J Glaucoma. 2018; 27 (11): 939–49. doi: 10.1097/IJG.0000000000001068
4. Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014; 121 (11): 2081–90. doi: 10.1016/j.ophtha.2014.05.013
5. Five-year follow-up of the Fluorouracil Filtering Surgery Study. The Fluorouracil Filtering Surgery Study Group. Am J Ophthalmol. 1996 Apr; 121 (4): 349–66. doi: 10.1016/s0002-9394(14)70431-3
6. Clinical Gidelines “Primary open angle glaucoma” (аpproved by the Ministry of Health of the Russian Federation, 17.08.2024) (In Russ.). http://avo-portal.ru/documents/fkr/Klinicheskie_rekomendacii_POUG_2022.pdf
7. Baker ND, Barnebey HS, Moster MR, et al. Ab-externo microshunt versus trabeculectomy in primary open-angle glaucoma: One-year results from a 2-year randomized, multicenter study. Ophthalmology. 2021; 128 (12): 1710–21. doi: 10.1016/j.ophtha.2021.05.023
8. Batlle JF, Corona A, Albuquerque R. Long-term results of the PRESERFLO microshunt in patients with primary open-angle glaucoma from a singlecenter nonrandomized study. J Glaucoma. 2021; 30 (3): 281–6. doi: 10.1097/IJG.0000000000001734
9. Beckers HJM, Aptel F, Webers CAB, et al. Safety and effectiveness of the PRESERFLO(R) microshunt in primary open-angle glaucoma: Results from a 2-year multicenter Study. Ophthalmol Glaucoma. 2022; 5 (2): 195–209. doi: 10.1016/j.ogla.2021.07.008
10. Durr GM, Schlenker MB, Samet S, Ahmed IIK. One-year outcomes of standalone ab externo SIBS microshunt implantation in refractory glaucoma. Br J Ophthalmol. 2022; 106 (1): 71–9. doi: 10.1136/bjophthalmol-2020-317299
11. Fea AM, Laffi GL, Martini E, et al. Effectiveness of microshunt in patients with primary open-angle and pseudoexfoliative glaucoma: A retrospective European multicenter study. Ophthalmol Glaucoma. 2022; 5 (2): 210–8. doi: 10.1016/j.ogla.2021.08.005
12. Jamke M, Herber R, Haase MA, et al. PR ESERFLO MicroShunt versus trabeculectomy: 1-year results on efficacy and safety. Graefes Arch Clin Exp Ophthalmol. 2023; 261 (10): 2901–15. doi: 10.1007/s00417-023-06075-4
13. Nobl M, Freissinger S, Kassumeh S, Priglinger S, Mackert MJ. One-year outcomes of microshunt implantation in pseudoexfoliation glaucoma. PLoS One. 2021; 16 (8): e0256670. doi: 10.1371/journal.pone.0256670
14. Panarelli JF, Moster MR, Garcia-Feijoo J, et al. Ab-externo microshunt versus trabeculectomy in primary open-angle glaucoma: Two-year results from a randomized, multicenter study. Ophthalmology. 2024; 131 (3): 266–76. doi: 10.1016/j.ophtha.2023.09.023
15. Pillunat KR, Herber R, Haase MA, et al. PRESERFLO MicroShunt versus trabeculectomy: first results on efficacy and safety. Acta Ophthalmol. 2022; 100 (3): e779-e90. doi: 10.1111/aos.14968
16. Triolo G, Wang J, Aguilar-Munoa S, Jayaram H, Barton K. Preserflo microshunt implant for the treatment of refractory uveitic glaucoma: 36-month outcomes. Eye (Lond). 2023; 37 (12): 2535–41. doi: 10.1038/s41433-022-02368-w
Review
For citations:
Zhuravleva A.N., Petrov S.Yu., Starostina A.V., Kalinina O.M., Filippova O.M., Kosakyan S.M., Markelova O.I. Early results of Preserflo MicroShunt implantation in primary open-angle glaucoma. Russian Ophthalmological Journal. 2025;18(4):34-38. (In Russ.) https://doi.org/10.21516/2072-0076-2025-18-4-34-38
Views:
26
Email this article 